ReviewJournal of ovarian research2025
An updated look into reactive oxygen species and cyclophosphamide-induced ovarian damage.
Review in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactobacillus salivarius li01 alleviates premature ovarian insufficiency via gut microbiota-mediated modulation of tryptophan metabolism.NPJ science of food · 2026Article
- A review of immunosuppressive therapy in the context of uterine VCA and pregnancy.Frontiers in transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is estimated that 70-75% of cancer survivors are interested in parenthood with an astounding 80% struggling with reduced fertility. Cancer treatments can deteriorate the ovarian primordial follicular pool and reduce the quality of fertilizable eggs through cytotoxicity and induction of premature ovarian insufficiency (POI). Cyclophosphamide is one of the most commonly used chemotherapeutic agents and is also utilized as an immunosuppressant in autoimmune diseases and in bone marrow transplants. Accordingly, those treated with cyclophosphamide face increased risks of POI and infertility, potentially arising from the toxic effects of its metabolites acrolein and phosphoramide mustard. The downstream accumulation of oxidative stress mediated by reactive oxygen species (ROS) from mitochondrial damage, activation of apoptotic pathways, and the disruption of enzymatic and non-enzymatic machinery may facilitate premature follicle activation, follicular apoptosis, and oocyte quality deterioration resulting in the loss of the ovarian reserve and POI. Furthermore, direct disruption of key antioxidants, such as superoxide dismutase (SOD) and glutathione (GSH), by acrolein and myeloperoxidase (MPO) may play a key role in ovarian disruption and the worsening oxidative state in those seeking treatment with cyclophosphamide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.